← Back to Search

Other

Treatment A: HFO propellant only MDI for Asthma

Phase 3

Waitlist Available

Led By David Miller, MD

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 36 days

Awards & highlights

Study Summary

This trial tested whether a new type of inhaler caused less breathing problems for people with asthma.

Eligible Conditions

Asthma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 36 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 36 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline FEV1 to 15-min post-dose

Secondary outcome measures

Cumulative incidence of bronchospasm events

Safety and tolerability will be evaluated in terms of AEs

Other outcome measures

Repeated measurements of change from baseline in FEV1 at 5, 15, and 30 minutes post-dose during each treatment period

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Treatment A: HFO propellant only MDIExperimental Treatment1 Intervention

Test arm, 4 inhalations per dose

Group II: Treatment B: HFA propellant only MDIActive Control1 Intervention

Reference arm, 4 inhalations per dose

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

HFO MDI

2023

Completed Phase 3

~60

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor

4,262 Previous Clinical Trials

288,595,190 Total Patients Enrolled

328 Trials studying Asthma

639,582 Patients Enrolled for Asthma

David Miller, MDPrincipal InvestigatorNortheast Medical Research Associates, Inc.

3 Previous Clinical Trials

106 Total Patients Enrolled

Craig LaForce, MDPrincipal InvestigatorNorth Carolina Clinical Research

2 Previous Clinical Trials

558 Total Patients Enrolled

1 Trials studying Asthma

408 Patients Enrolled for Asthma

Media Library

HFA MDI (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05850494 — Phase 3

Asthma Research Study Groups: Treatment A: HFO propellant only MDI, Treatment B: HFA propellant only MDI

Asthma Clinical Trial 2023: HFA MDI Highlights & Side Effects. Trial Name: NCT05850494 — Phase 3

HFA MDI (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05850494 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must potential participants meet to be eligible for this clinical trial?

"Applicants for this asthmatic medical trial are required to be aged between 18 and 45. A total of 52 individuals will eventually take part in the research program."

Answered by AI

Is this investigation open to individuals past 25 years of age?

"The prerequisites for this trial demand that participants be aged between 18 to 45. Those with an age lower than 18 can look into one of the 143 trials available, whereas those over 65 may consider any of the 214 ongoing studies."

Answered by AI

Is enrollment in this investigation ongoing?

"Clinicaltrials.gov indicates that, despite the initial posting of this trial on May 2nd 2023 and its last update occurring April 28th 2023, it is no longer recruiting patients at this time. Fortunately, there are currently 347 other clinical trials actively looking for participants."

Answered by AI

Has the FDA given approval for Treatment A, which utilizes High Flow Oxygen propellant in a Metered Dose Inhaler?

"Our experts at Power graded the safety of Treatment A: HFO propellant only MDI with a 3 due to the evidence from multiple studies that supports its efficacy and security."

Answered by AI

How many sites within the state are facilitating this research endeavor?

"Prospective patients can enrol in this medical experiment at The Clinical Research Center, LLC. in Saint Louis, Missouri; North carolina Clinical Research in Raleigh, North Carolina; EPIMRD Inc. dba/Western Sky Medical Research in El Paso, Texas and 4 other sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

2023. "Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05850494.